Notch and VEGF pathways play distinct but complementary roles in tumor angiogenesis

Vascular Cell

Volumn 5, Issue 1, 2013, Pages

  Hernandez, Sonia L ^a   Banerjee, Debarshi ^a   Garcia, Alejandro ^a   Kangsamaksin, Thaned ^a   Cheng, Wei Yi ^b   Anastassiou, Dimitris ^b   Funahashi, Yasuhiro ^a   Kadenhe Chiweshe, Angela ^a   Shawber, Carrie J ^a   Kitajewski, Jan K ^a   Kandel, Jessica J ^a   Yamashiro, Darrell J ^a  

^a NewYork Presbyterian Hospital   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Angiogenesis; Bevacizumab; Neuroblastoma; Notch; Vascular endothelial growth factor

Indexed keywords

ALBUMIN; BEVACIZUMAB; NOTCH1 RECEPTOR; PLACEBO;

ANGIOGENESIS; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BLOOD VESSEL; CONTROLLED STUDY; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA; NONHUMAN; PERICYTE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84884515549     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-5-17     Document Type: Article

References (18)

1. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. Glade Bender JL, Adamson PC, Reid JM, Xu L, Baruchel S, Shaked Y, Kerbel RS, Cooney-Qualter EM, Stempak D, Chen HX, et al. J Clin Oncol 2008 26 399 405 10.1200/JCO.2007.11.9230 18202416 (Pubitemid 351171691)
2. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, et al. Proc Natl Acad Sci USA 2002 99 11399 11404 10.1073/pnas.172398399 12177446 (Pubitemid 34920937)
3. Vascular endothelial growth factor blockade rapidly elicits alternative proangiogenic pathways in neuroblastoma. Zaghloul N, Hernandez SL, Bae JO, Huang J, Fisher JC, Lee A, Kadenhe-Chiweshe A, Kandel JJ, Yamashiro DJ, Int J Oncol 2009 34 401 407 19148474
4. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N, Nature 1993 362 841 844 10.1038/362841a0 7683111 (Pubitemid 23132159)
5. A notch1 ectodomain construct inhibits endothelial notch signaling, tumor growth, and angiogenesis. Funahashi Y, Hernandez SL, Das I, Ahn A, Huang J, Vorontchikhina M, Sharma A, Kanamaru E, Borisenko V, Desilva DM, et al. Cancer Res 2008 68 4727 4735 10.1158/0008-5472.CAN-07-6499 18559519
6. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP, Proc Natl Acad Sci USA 2005 102 15545 15550 10.1073/pnas.0506580102 16199517 (Pubitemid 41528093)
7. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM, Am J Pathol 2003 163 1801 1815 10.1016/S0002-9440(10)63540-7 14578181 (Pubitemid 37310012)
8. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, et al. Nature 2006 444 1083 1087 10.1038/nature05313 17183323 (Pubitemid 46018529)
9. Notch activation induces endothelial cell cycle arrest and participates in contact inhibition: role of p21Cip1 repression. Noseda M, Chang L, McLean G, Grim JE, Clurman BE, Smith LL, Karsan A, Mol Cell Biol 2004 24 8813 8822 10.1128/MCB.24.20.8813-8822.2004 15456857 (Pubitemid 39313888)
10. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial endothelial cells: implications for modulating arteriogenesis and angiogenesis. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC, Herlyn M, Mol Cell Biol 2003 23 14 25 10.1128/MCB.23.1.14-25.2003 12482957 (Pubitemid 36008497)
11. Notch regulates the angiogenic response via induction of VEGFR-1. Funahashi Y, Shawber CJ, Vorontchikhina M, Sharma A, Outtz HH, Kitajewski J, J Angiogenes Res 2010 2 3 10.1186/2040-2384-2-3 20298529
12. Notch alters VEGF responsiveness in human and murine endothelial cells by direct regulation of VEGFR-3 expression. Shawber CJ, Funahashi Y, Francisco E, Vorontchikhina M, Kitamura Y, Stowell SA, Borisenko V, Feirt N, Podgrabinska S, Shiraishi K, et al. J Clin Invest 2007 117 3369 3382 10.1172/JCI24311 17948123 (Pubitemid 350096993)
13. Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. Taylor KL, Henderson AM, Hughes CC, Microvasc Res 2002 64 372 383 10.1006/mvre.2002.2443 12453432 (Pubitemid 35370739)
14. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G, Nature 2006 444 1032 1037 10.1038/nature05355 17183313 (Pubitemid 46018516)
15. Therapeutic antibody targeting of individual Notch receptors. Wu Y, Cain-Hom C, Choy L, Hagenbeek TJ, de Leon GP, Chen Y, Finkle D, Venook R, Wu X, Ridgway J, et al. Nature 2010 464 1052 1057 10.1038/nature08878 20393564
16. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. Soffer SZ, Moore JT, Kim E, Huang J, Yokoi A, Manley C, O'Toole K, Stolar C, Middlesworth W, Yamashiro DJ, Kandel JJ, Journal of pediatric surgery 2001 36 1177 1181 10.1053/jpsu.2001.25747 11479851 (Pubitemid 32705699)
17. Modes of resistance to anti-angiogenic therapy. Bergers G, Hanahan D, Nature reviews Cancer 2008 8 592 603 10.1038/nrc2442 18650835
18. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Benedito R, Roca C, Sorensen I, Adams S, Gossler A, Fruttiger M, Adams RH, Cell 2009 137 1124 1135 10.1016/j.cell.2009.03.025 19524514